Dyslipidemia associated with chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Clinical Biochemistry

Background:

• Cardiovascular disease (CVD) is a leading cause of death in individuals with impaired renal function.
• Dyslipidemia, a significant risk factor for CVD in the general population, is prevalent in chronic kidney disease (CKD) patients due to altered lipoprotein metabolism.

Purpose of the Study:

• To review the pathogenesis and management strategies for dyslipidemia in CKD patients.
• To analyze lipid abnormalities across different stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis.
• To report findings on the efficacy of hypolipidemic drugs in reducing cardiovascular morbidity and mortality in CKD.

Main Methods:

• Literature review analyzing studies on lipid metabolism in CKD.
• Examination of lipid profiles in predialysis, hemodialysis, and peritoneal dialysis populations.
• Analysis of clinical trial data on hypolipidemic drug interventions in CKD patients.

Main Results:

• CKD is associated with distinct alterations in lipoprotein metabolism, contributing to dyslipidemia.
• Lipid abnormalities vary depending on the stage of renal impairment and dialysis modality.
• Evidence regarding the impact of hypolipidemic drugs on cardiovascular outcomes in CKD is presented and discussed.

Conclusions:

• Dyslipidemia is a critical issue in CKD management, necessitating targeted therapeutic approaches.
• Understanding CKD-specific lipid alterations is crucial for effective CVD risk reduction.
• Further research on hypolipidemic drug efficacy in CKD is warranted to optimize patient care and improve cardiovascular health.